Download these slides from a CCO Live Webinar to get up to date on the latest clinical data informing optimal treatment of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, including guidance on testing for RET alterations and monitoring for and managing common adverse events with new-generation, selective RET inhibitors.
Download these slides from a CCO Live Webinar to review the latest clinical data informing optimal treatment of advanced RET fusion–positive NSCLC, including monitoring for and managing common adverse events with new-generation, selective RET inhibitors.
Download these slides from a CCO Live Webinar to review the latest clinical data informing optimal treatment of metastatic RET-altered thyroid cancer.
Download these slides to review expert insights from a pathologist on best testing practices to identify patients with advanced thyroid cancer and NSCLC eligible for treatment with a RET specific inhibitor.
Download this short summary slideset of key takeaways from a live CCO Webinar featuring expert guidance on the optimal management of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.
Download this short summary slideset of key takeaways from a live CCO Webinar featuring a molecular pathologist and medical oncologists with expertise in lung and thyroid cancer discussing the latest clinical data on optimal treatment of RET-altered disease with new-generation, selective RET inhibitors.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.